Univariate analysis of the association between different variables and clinical failure at day 21
| Variable . | Category . | No. of patients who failed at day 21/no. of patients in category (%) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Gender | male | 15/179 (8.4) | Reference | |
| female | 9/96 (9.4) | 1.12 (0.51–2.46) | 0.78 | |
| Age | ≤65 | 4/81 (4.9) | reference | |
| >65 | 20/193 (10.4) | 2.09 (0.74–5.95) | 0.147 | |
| Mechanical ventilation | no | 21/266 (7.9) | reference | |
| yes | 3/9 (33.3) | 4.22 (1.54–11.63) | 0.035 | |
| Charlson index | <2 | 5/132 (3.8) | reference | |
| ≥2 | 19/143 (13.3) | 3.51 (1.35–9.09) | 0.005 | |
| Pitt score | 0–1 | 7/177 (4.0) | reference | |
| ≥2 | 17/97 (17.5) | 4.42 (1.90–10.31) | 0.0001 | |
| Onset | nosocomial | 17/167 (10.2) | reference | |
| community | 7/108 (6.5) | 0.64 (0.27–1.48) | 0.289 | |
| Source | urinary tract | 5/71 (7.0) | reference | |
| others | 19/204 (9.3) | 1.32 (0.51–3.41) | 0.559 | |
| biliary tract | 5/133 (3.8) | reference | ||
| others | 19/142 (13.4) | 3.56 (1.37–9.26) | 0.005 | |
| abdominal | 5/27 (18.5) | reference | ||
| others | 19/248 (7.7) | 0.414 (0.16–1.01) | 0.071 | |
| vascular catheter | 1/12 (8.3) | reference | ||
| others | 23/263 (8.7) | 1.049 (0.15–7.14) | 1 | |
| respiratory | 6/15 (40.0) | reference | ||
| others | 18/260 (6.9) | 0.173 (0.08–0.37) | 0.001 | |
| Severe sepsis or septic shock | no | 8/182 (4.4) | reference | |
| yes | 16/92 (17.4) | 3.95 (1.76–8.93) | 0.0001 | |
| MIC of piperacillin/tazobactam | low | 22/248 (8.9) | reference | |
| borderline | 2/27 (7.4) | 0.83 (0.21–3.36) | 1 | |
| Aetiology | E. coli | 15/174 (8.6) | reference | |
| others | 9/101 (8.9) | 1.03 (0.47–2.28) | 0.934 | |
| ESBL producer | no | 22/262 (8.4) | reference | |
| yes | 2/13 (15.4) | 1.831 (0.48–0.69) | 0.316 | |
| Antibiotic changed | no | 11/59 (18.6) | reference | |
| yes | 13/216 (6.0) | 0.322 (0.15–0.68) | 0.002 | |
| 50% fT>MIC | no | 0/4 (0) | ||
| yes | 20/237 (8.4) | — | 1 | |
| 100% fT>MIC | no | 5/45 (11.1) | reference | |
| yes | 15/196 (7.7) | 0.689 (0.26–1.79) | 0.547 |
| Variable . | Category . | No. of patients who failed at day 21/no. of patients in category (%) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Gender | male | 15/179 (8.4) | Reference | |
| female | 9/96 (9.4) | 1.12 (0.51–2.46) | 0.78 | |
| Age | ≤65 | 4/81 (4.9) | reference | |
| >65 | 20/193 (10.4) | 2.09 (0.74–5.95) | 0.147 | |
| Mechanical ventilation | no | 21/266 (7.9) | reference | |
| yes | 3/9 (33.3) | 4.22 (1.54–11.63) | 0.035 | |
| Charlson index | <2 | 5/132 (3.8) | reference | |
| ≥2 | 19/143 (13.3) | 3.51 (1.35–9.09) | 0.005 | |
| Pitt score | 0–1 | 7/177 (4.0) | reference | |
| ≥2 | 17/97 (17.5) | 4.42 (1.90–10.31) | 0.0001 | |
| Onset | nosocomial | 17/167 (10.2) | reference | |
| community | 7/108 (6.5) | 0.64 (0.27–1.48) | 0.289 | |
| Source | urinary tract | 5/71 (7.0) | reference | |
| others | 19/204 (9.3) | 1.32 (0.51–3.41) | 0.559 | |
| biliary tract | 5/133 (3.8) | reference | ||
| others | 19/142 (13.4) | 3.56 (1.37–9.26) | 0.005 | |
| abdominal | 5/27 (18.5) | reference | ||
| others | 19/248 (7.7) | 0.414 (0.16–1.01) | 0.071 | |
| vascular catheter | 1/12 (8.3) | reference | ||
| others | 23/263 (8.7) | 1.049 (0.15–7.14) | 1 | |
| respiratory | 6/15 (40.0) | reference | ||
| others | 18/260 (6.9) | 0.173 (0.08–0.37) | 0.001 | |
| Severe sepsis or septic shock | no | 8/182 (4.4) | reference | |
| yes | 16/92 (17.4) | 3.95 (1.76–8.93) | 0.0001 | |
| MIC of piperacillin/tazobactam | low | 22/248 (8.9) | reference | |
| borderline | 2/27 (7.4) | 0.83 (0.21–3.36) | 1 | |
| Aetiology | E. coli | 15/174 (8.6) | reference | |
| others | 9/101 (8.9) | 1.03 (0.47–2.28) | 0.934 | |
| ESBL producer | no | 22/262 (8.4) | reference | |
| yes | 2/13 (15.4) | 1.831 (0.48–0.69) | 0.316 | |
| Antibiotic changed | no | 11/59 (18.6) | reference | |
| yes | 13/216 (6.0) | 0.322 (0.15–0.68) | 0.002 | |
| 50% fT>MIC | no | 0/4 (0) | ||
| yes | 20/237 (8.4) | — | 1 | |
| 100% fT>MIC | no | 5/45 (11.1) | reference | |
| yes | 15/196 (7.7) | 0.689 (0.26–1.79) | 0.547 |
Univariate analysis of the association between different variables and clinical failure at day 21
| Variable . | Category . | No. of patients who failed at day 21/no. of patients in category (%) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Gender | male | 15/179 (8.4) | Reference | |
| female | 9/96 (9.4) | 1.12 (0.51–2.46) | 0.78 | |
| Age | ≤65 | 4/81 (4.9) | reference | |
| >65 | 20/193 (10.4) | 2.09 (0.74–5.95) | 0.147 | |
| Mechanical ventilation | no | 21/266 (7.9) | reference | |
| yes | 3/9 (33.3) | 4.22 (1.54–11.63) | 0.035 | |
| Charlson index | <2 | 5/132 (3.8) | reference | |
| ≥2 | 19/143 (13.3) | 3.51 (1.35–9.09) | 0.005 | |
| Pitt score | 0–1 | 7/177 (4.0) | reference | |
| ≥2 | 17/97 (17.5) | 4.42 (1.90–10.31) | 0.0001 | |
| Onset | nosocomial | 17/167 (10.2) | reference | |
| community | 7/108 (6.5) | 0.64 (0.27–1.48) | 0.289 | |
| Source | urinary tract | 5/71 (7.0) | reference | |
| others | 19/204 (9.3) | 1.32 (0.51–3.41) | 0.559 | |
| biliary tract | 5/133 (3.8) | reference | ||
| others | 19/142 (13.4) | 3.56 (1.37–9.26) | 0.005 | |
| abdominal | 5/27 (18.5) | reference | ||
| others | 19/248 (7.7) | 0.414 (0.16–1.01) | 0.071 | |
| vascular catheter | 1/12 (8.3) | reference | ||
| others | 23/263 (8.7) | 1.049 (0.15–7.14) | 1 | |
| respiratory | 6/15 (40.0) | reference | ||
| others | 18/260 (6.9) | 0.173 (0.08–0.37) | 0.001 | |
| Severe sepsis or septic shock | no | 8/182 (4.4) | reference | |
| yes | 16/92 (17.4) | 3.95 (1.76–8.93) | 0.0001 | |
| MIC of piperacillin/tazobactam | low | 22/248 (8.9) | reference | |
| borderline | 2/27 (7.4) | 0.83 (0.21–3.36) | 1 | |
| Aetiology | E. coli | 15/174 (8.6) | reference | |
| others | 9/101 (8.9) | 1.03 (0.47–2.28) | 0.934 | |
| ESBL producer | no | 22/262 (8.4) | reference | |
| yes | 2/13 (15.4) | 1.831 (0.48–0.69) | 0.316 | |
| Antibiotic changed | no | 11/59 (18.6) | reference | |
| yes | 13/216 (6.0) | 0.322 (0.15–0.68) | 0.002 | |
| 50% fT>MIC | no | 0/4 (0) | ||
| yes | 20/237 (8.4) | — | 1 | |
| 100% fT>MIC | no | 5/45 (11.1) | reference | |
| yes | 15/196 (7.7) | 0.689 (0.26–1.79) | 0.547 |
| Variable . | Category . | No. of patients who failed at day 21/no. of patients in category (%) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Gender | male | 15/179 (8.4) | Reference | |
| female | 9/96 (9.4) | 1.12 (0.51–2.46) | 0.78 | |
| Age | ≤65 | 4/81 (4.9) | reference | |
| >65 | 20/193 (10.4) | 2.09 (0.74–5.95) | 0.147 | |
| Mechanical ventilation | no | 21/266 (7.9) | reference | |
| yes | 3/9 (33.3) | 4.22 (1.54–11.63) | 0.035 | |
| Charlson index | <2 | 5/132 (3.8) | reference | |
| ≥2 | 19/143 (13.3) | 3.51 (1.35–9.09) | 0.005 | |
| Pitt score | 0–1 | 7/177 (4.0) | reference | |
| ≥2 | 17/97 (17.5) | 4.42 (1.90–10.31) | 0.0001 | |
| Onset | nosocomial | 17/167 (10.2) | reference | |
| community | 7/108 (6.5) | 0.64 (0.27–1.48) | 0.289 | |
| Source | urinary tract | 5/71 (7.0) | reference | |
| others | 19/204 (9.3) | 1.32 (0.51–3.41) | 0.559 | |
| biliary tract | 5/133 (3.8) | reference | ||
| others | 19/142 (13.4) | 3.56 (1.37–9.26) | 0.005 | |
| abdominal | 5/27 (18.5) | reference | ||
| others | 19/248 (7.7) | 0.414 (0.16–1.01) | 0.071 | |
| vascular catheter | 1/12 (8.3) | reference | ||
| others | 23/263 (8.7) | 1.049 (0.15–7.14) | 1 | |
| respiratory | 6/15 (40.0) | reference | ||
| others | 18/260 (6.9) | 0.173 (0.08–0.37) | 0.001 | |
| Severe sepsis or septic shock | no | 8/182 (4.4) | reference | |
| yes | 16/92 (17.4) | 3.95 (1.76–8.93) | 0.0001 | |
| MIC of piperacillin/tazobactam | low | 22/248 (8.9) | reference | |
| borderline | 2/27 (7.4) | 0.83 (0.21–3.36) | 1 | |
| Aetiology | E. coli | 15/174 (8.6) | reference | |
| others | 9/101 (8.9) | 1.03 (0.47–2.28) | 0.934 | |
| ESBL producer | no | 22/262 (8.4) | reference | |
| yes | 2/13 (15.4) | 1.831 (0.48–0.69) | 0.316 | |
| Antibiotic changed | no | 11/59 (18.6) | reference | |
| yes | 13/216 (6.0) | 0.322 (0.15–0.68) | 0.002 | |
| 50% fT>MIC | no | 0/4 (0) | ||
| yes | 20/237 (8.4) | — | 1 | |
| 100% fT>MIC | no | 5/45 (11.1) | reference | |
| yes | 15/196 (7.7) | 0.689 (0.26–1.79) | 0.547 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
